Pertuzumab

Drug Profile

Pertuzumab

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab 2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Roche; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Gastric cancer; Ovarian cancer
  • Phase II Colorectal cancer
  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop pertuzumab in Cancer
  • 17 Nov 2016 National Institute for Health and Care Excellence (NICE) recommend pertuzumab for Breast cancer (Combination therapy, Early-stage disease, Neoadjuvant therapy) in United Kingdom
  • 01 Aug 2016 Roche initiates enrolment in a phase III trial for Breast cancer (Combination therapy, First-line, Metastatic) in China (NCT02896855)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top